Scientific Article

Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial

Patients with cirrhosis and portal hypertension face a high risk of complications. Besides their anti-inflammatory and antifibrotic effects, statins may reduce portal pressure and thus the risk of complications andmortality. We aimed to investigate the effects of atorvastatin on hospital admissions, mortality, inflammation, and lipidomics in cirrhosis with portal hypertension.

View online!

Kronborg, T.M., Schierwagen, R., Trošt, K., Gao, Q., Moritz, T., Bendtsen, F., Gantzel, R.H., Andersen, M.L., Teisner, A.S., Grønbæk, H., Hobolth, L., Møller, S., Trebicka, J., Kimer, N. Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial. Hepatol Commun. 2023 Dec 1;7(12). doi: 10.1097/HC9.0000000000000332. PMID: 38051553; PMCID: PMC10697620.

The Role of Hypoxia-Inducible Factor 1 Alpha in Acute-on-Chronic Liver Failure
Epidemiology of liver transplantation and post-LT complications in Germany: nationwide study (2005-2018)